糖心原创

Home⇛The Philippine Journal of Biochemistry and Molecular Biology (PJBMB)⇛vol. 1 no. 1 & 2 (2020)

Mass Spectrometry and Proteomics as Emerging Technologies for Breast Cancer

Maritess D. Cation | Maria Cristina M. Ramos

Discipline: Biological and Sport Sciences

 

Abstract:

Breast cancer among women has shown a steady increase in incidence and mortality rates in the Philippines, and around the globe. To date, there are a few and limited biomarkers approved for diagnosis and target for therapy. Some tumor tissues do not express any valid biomarkers in clinical tests, and patients from this group are unlikely to respond well to hormone therapy.Here,we presented a comprehensive literature resources citing potential biomarkers found fromomicsbased assays. More importantly, we also presented a rich list of significantly expressed novel protein biomarkers found through mass spectrometry and proteomic analysis. By applying mass spectrometry technology, we can achieve deep and large proteomic profiles from cells and tissues. The latest developments in mass spectrometry and its application will bring a big impact in breast cancer research and drug discovery as we find novel proteins and its association to various pathways linked to the hallmarks of breast cancer.



References:

  1. WHO, Who Report on Cancer. 2020.
  2. NCI, “NCI Center to Reduce Cancer Health Disparities,” 2019. [Online]. Available: . [Accessed: 28-May-2019].
  3. A.Cooper, On the anatomy of the breast. Jefferson, 1840.
  4. M. L.Marinovich et al., “Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis,” BMC Cancer, vol. 15, p. 662, Oct.2015.
  5. M.Mayo Clinic, “Breast Cancer,” 2019, 2019. [Online]. Available: .
  6. C. J.Watson and W. T.Khaled, “Mammary development in the embryo and adult: a journey of morphogenesis and commitment,” Development, vol. 135, no. 6, pp. 995 LP – 1003, Mar.2008.
  7. J. H.Krege et al., “Generation and reproductive phenotypes of mice lacking estrogen receptor beta,” Proc. Natl.Acad.Sci. U.S.A., vol. 95, no. 26, pp. 15677–15682, Dec.1998.
  8. W.Ruan and D. L.Kleinberg, “Insulin-Like Growth Factor I Is Essential for Terminal End Bud Formation and Ductal Morphogenesis during Mammary Development1,” Endocrinology, vol. 140, no. 11, pp. 5075–5081, Nov.1999.
  9. J.McBryan, J.Howlin, S.Napoletano, and F.Martin, “Amphiregulin: Role in Mammary Gland Development and Breast Cancer,” J. Mammary Gland Biol. Neoplasia, vol. 13, pp. 159–169, Jul.2008.
  10. S. R.Oakes, H. N.Hilton, and C. J.Ormandy, “The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium,” Breast Cancer Res., vol. 8, no. 2, p. 207, 2006.
  11. T. R.Milanese et al., “Age-related lobular involution and risk of breast cancer.,” J. Natl. Cancer Inst., vol. 98, no. 22, pp. 1600–1607, Nov.2006.
  12. V.Sangwan and M.Park, “Receptor tyrosine kinases: role in cancer progression,” Curr. Oncol., vol. 13, no. 5, pp. 191–193, Oct.2006.
  13. S. P.Chiang, G. S.Karagiannis, J. S.Condeelis, and J. E.Segall, “Abstract 1844: Investigating the role of amphiregulin in breast cancer,” Cancer Res., vol. 77, no. 13 Supplement, pp. 1844 LP – 1844, Jul.2017.
  14. S.Lee et al., “Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.,” Am. J. Pathol., vol. 171, no. 1, pp. 252–262, Jul.2007.
  15. S.Mao et al., “Abstract 5114: The role of amphiregulin in mammary gland development and breast cancer,” Cancer Res., vol. 78, no. 13 Supplement, pp. 5114 LP – 5114, Jul.2018.
  16. A.Baillo, C.Giroux, and S. P.Ethier, “Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer.,” J. Cell. Physiol., vol. 226, no. 10, pp. 2691–2701, Oct.2011.
  17. S.Rao, S. J. F.Cronin, V.Sigl, and J. M.Penninger, “RANKL and RANK: From Mammalian Physiology to Cancer Treatment,” Trends Cell Biol., vol. 28, no. 3, pp. 213–223, 2018.
  18. E.Gonzalez-Suarez et al., “RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.,” Nature, vol. 468, no. 7320, pp. 103–107, Nov.2010.
  19. D.Schramek et al., “Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.,” Nature, vol. 468, no. 7320, pp. 98–102, Nov.2010.
  20. D. C.Radisky and L. C.Hartmann, “Mammary involution and breast cancer risk: transgenic models and clinical studies,” J. Mammary Gland Biol. Neoplasia, vol. 14, no. 2, pp. 181–191, Jun.2009.
  21. R. W. E.Clarkson and C. J.Watson, “Microarray analysis of the involution switch.,” J. Mammary Gland Biol. Neoplasia, vol. 8, no. 3, pp. 309–319, Jul.2003.
  22. L.T.Bemis and P.Schedin, “Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion.,” Cancer Res., vol. 60, no. 13, pp. 3414–3418, Jul.2000.
  23. M.Xue et al., “Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56,” Oncogenesis, vol. 8, no. 5, p. 30, 2019.
  24. J.Wang and B.Xu, “Targeted therapeutic options and future perspectives for HER2-positive breast cancer,” Signal Transduct. Target. Ther., vol. 4, no. 1, p. 34, 2019.
  25. L.Xia et al., “Role of the NFκB-signaling pathway in cancer,” Onco. Targets. Ther., vol. 11, pp. 2063–2073, Apr.2018.
  26. T. H. B.Gomig et al., “Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer,” J. Proteomics, vol. 199, no. August 2018, pp. 1–14, 2019.
  27. E.Presti, Daniele and Quaquarini, “The PI3K/AKT/ mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments,” Cancers (Basel)., vol. 11, no. 9, pp. 1–20, 2019.
  28. B. M.Krishna et al., “Notch signaling in breast cancer: From pathway analysis to therapy,” Cancer Lett., vol. 461, pp. 123–131, 2019.
  29. M. A.Gillette et al., “Proteogenomics connects somatic mutations to signalling in breast cancer,” Nature, pp. 1–19, 2016.
  30. H. J.Burstein, “The distinctive nature of HER2- positive breast cancers.,” N. Engl. J. Med., vol. 353, no. 16, pp. 1652–1654, Oct.2005.
  31. NIH, “Breast Cancer,” 2019. [Online]. Available: .
  32. K. A.Metcalfe et al., “The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.,” Clin. Genet., vol. 93, no. 5, pp. 1063–1068, May2018.
  33. Z.Mitri, T.Constantine, and R.O’Regan, “The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy,” Chemother. Res. Pract., vol. 2012, p. 743193, 2012.
  34. M. C.Figueroa-Magalhães, D.Jelovac, R.Connolly, and A. C.Wolff, “Treatment of HER2-positive breast cancer,” Breast, vol. 23, no. 2, pp. 128–136, Apr.2014.
  35. M.Dowsett et al., “Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group,” J. Natl. Cancer Inst., vol. 103, no. 22, pp. 1656–1664, Nov.2011.
  36. M.Abubakar et al., “Combined quantitative measures of ER , PR , HER2 , and KI67 provide more prognostic information than categorical combinations in luminal breast cancer,” Mod. Pathol., pp. 1244–1256, 2019.
  37. F. J.Candido et al., “An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation,” pp. 1–13, 2017.
  38. A.Vaishnavi, A. T.Le, and R. C.Doebele, “TRKing down an old oncogene in a new era of targeted therapy.,” Cancer Discov., vol. 5, no. 1, pp. 25–34, Jan.2015.
  39. J. J.Lee, K.Loh, and Y.-S.Yap, “PI3K/Akt/mTOR inhibitors in breast cancer,” Cancer Biol. Med., vol. 12, no. 4, pp. 342–354, Dec.2015.
  40. O.Willis et al., “PIK3CA gene aberrancy and role in targeted therapy of solid malignancies,” Cancer Gene Ther., 2020.
  41. Y. F.Hou, M.F., Chen, Y.L., Tseng, T.F., Lin, C.M., Chen, M.S., Huang, C.J., Huang, Y.S., Hsieh, J.S., Huang, T.J., Jong, S.B., Huang, “Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer,” Kaohsiung J. Med. Sci., 1999.
  42. C.VanPoznak, L. N.Harris, and M. R.Somerfield, “Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline,” J. Oncol. Pract., vol. 11, no. 6, pp. 514–516, Jul.2015.
  43. A. M.Kabel, “Tumor markers of breast cancer: New prospectives,” J. Oncol. Sci., vol. 3, no. 1, pp. 5–11, 2017.
  44. X.Zhe, M. L.Cher, and R. D.Bonfil, “Circulating tumor cells: finding the needle in the haystack,” Am. J. Cancer Res., vol. 1, no. 6, pp. 740–751, 2011.
  45. W. A.Osta et al., “EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy,” Cancer Res., vol. 64, no. 16, pp. 5818 LP – 5824, Aug.2004.
  46. S.Cotterill, “Cancer Genetics Web,” 2019. [Online]. Available: . [Accessed: 10-Jul-2020].
  47. E.Jarasch, R. A. Y. B.Nagle, M.Kaufmann, C.Maurer, and W. J.Bocker, “Differential Diagnosis of Benign Epithelial Proliferations and Carcinomas of the Breast Using Antibodies to Cytokeratins,” 1987.
  48. Y.Jing, J.Zhang, S.Waxman, and R.Mira-y-Lopez, “Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent.,” Differentiation., vol. 60, no. 2, pp. 109–117, May1996.
  49. M. B.Lustberg et al., “Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.,” Breast Cancer Res., vol. 16, no. 2, p. R23, Mar.2014.
  50. C. P .Leo, C.Leo, and T. D.Szucs, “Breast cancer drug approvals by the US FDA from 1949 to 2018,” Nat. Rev. Drug Discov., vol. 19, no. 1, p. 11, 2020.
  51. A.Garcia-Diaz et al., “Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.,” Cell Rep., vol. 19, no. 6, pp. 1189–1201, May2017.
  52. Y.Han, D.Liu, and L.Li, “PD-1/PD-L1 pathway: current researches in cancer,” Am. J. Cancer Res., vol. 10, no. 3, pp. 727–742, Mar.2020.
  53. F.Schütz, S.Stefanovic, L.Mayer, A.VonAu, C.Domschke, and C.Sohn, “PD-1/PD-L1 Pathway in Breast Cancer,” Oncol. Res. Treat., vol. 40, no. 5, pp. 294–297, 2017.
  54. A.Illiano, G.Pinto, C.Melchiorre, A.Carpentieri, V.Faraco, and A.Amoresano, “Protein Glycosylation Investigated by Mass Spectrometry: An Overview,” Cells, vol. 9, no. 9, pp. 1–22, 2020.
  55. K. A.Resing and N. G.Ahn, “Proteomics strategies for protein identification,” vol. 579, pp. 885–889, 2005.
  56. G.Büyükköro臒lu, D. D.Dora, F.Özdemir, and C.H谋zel, “Chapter 15 - Techniques for Protein Analysis,” D.Barh and V. B. T.-O. T. and B.-E.Azevedo, Eds.Academic Press, 2018, pp. 317–351.
  57. T. J.Griffin and R.Aebersold, “Advances in Proteome Analysis by Mass Spectrometry,” J. Biol. Chem., vol. 276, no. 49, pp. 45497–45500, 2001.
  58. S. B.Nukala, G.Baron, G.Aldini, M.Carini, and A.D’Amato, “Mass Spectrometry-based Label-free Quantitative Proteomics To Study the Effect of 3PO Drug at Cellular Level.,” ACS Med. Chem. Lett., vol. 10, no. 4, pp. 577–583, Apr.2019.
  59. M. W.Duncan and S. W.Hunsucker, “Proteomics as a tool for clinically relevant biomarker discovery and validation.,” Exp. Biol. Med. (Maywood)., vol. 230, no. 11, pp. 808–817, Dec.2005.
  60. F. M.White, “Quantitative phosphoproteomic analysis of signaling network dynamics.,” Curr. Opin. Biotechnol., vol. 19, no. 4, pp. 404–409, Aug.2008.
  61. A. P.Frei et al., “Direct identification of ligand-receptor interactions on living cells and tissues.,” Nat. Biotechnol., vol. 30, no. 10, pp. 997–1001, Oct.2012.
  62. R.Aebersold and M.Mann, “Mass spectrometry-based proteomics,” Nature, vol. 422, no. 6928, pp. 198–207, 2003.
  63. F.Desiere et al., “The PeptideAtlas project.,” Nucleic Acids Res., vol. 34, no. Database issue, pp. 655–658, 2006.
  64. G.Rosenberger et al., “A repository of assays to quantify 10,000 human proteins by SWATH-MS,” Sci. Data, vol. 1, no. 1, p. 140031, 2014.
  65. P.Palmowski et al., “The Generation of a Comprehensive Spectral Library for the Analysis of the Guinea Pig Proteome by SWATH-MS,” Proteomics, vol. 19, no. 15, pp. 1–5, 2019.
  66. Y.Lin, “In silico spectral libraries by deep learning facilitate data-independent acquisition proteomics,” Nat. Commun., pp. 1–11, 2020.
  67. E.Hoedt, G.Zhang, and T. A.Neubert, “Stable isotope labeling by amino acids in cell culture (SILAC) for quantitative proteomics.,” Adv. Exp. Med. Biol., vol. 806, pp. 93–106, 2014.
  68. S.Wiese, K. A.Reidegeld, H. E.Meyer, and B.Warscheid, “Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research.,” Proteomics, vol. 7, no. 3, pp. 340–350, Feb.2007.
  69. J.Muntel et al., “Comparison of Protein Quantification in a Complex Background by DIA and TMT Workflows with Fixed Instrument Time,” 2019.
  70. L. R.Zieske, “A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies.,” J. Exp. Bot., vol. 57, no. 7, pp. 1501–1508, 2006.
  71. L.Zhang and J. E.Elias, “Relative Protein Quantification Using Tandem Mass Tag Mass Spectrometry BT - Proteomics: Methods and Protocols,” L.Comai, J. E.Katz, and P.Mallick, Eds.New York, NY: Springer New York, 2017, pp. 185–198.
  72. D.Virág et al., “Current Trends in the Analysis of Post-translational Modifications,” Chromatographia, vol. 83, no. 1, pp. 1–10, 2020.
  73. B.Manadas, V. M.Mendes, J.English, and M. J.Dunn, “Peptide fractionation in proteomics approaches.,” Expert Rev. Proteomics, vol. 7, no. 5, pp. 655–663, Oct.2010.
  74. E. R.Sauter, “Reliable Biomarkers to Identify New and Recurrent Cancer,” Eur. J. breast Heal., vol. 13, no. 4, pp. 162–167, Oct.2017.
  75. E. M.Woo, D.Fenyo, B. H.Kwok, H.Funabiki, and B. T.Chait, “Efficient Identification of Phosphorylation by Mass Spectrometric Phosphopeptide Fingerprinting,” Anal. Chem., vol. 80, no. 7, pp. 2419–2425, Apr.2008.
  76. S. A.Beausoleil et al., “Large-scale characterization of HeLa cell nuclear phosphoproteins,” Proc. Natl. Acad. Sci. U. S. A., vol. 101, no. 33, pp. 12130–12135, 2004.
  77. C.Ludwig, L.Gillet, G.Rosenberger, S.Amon, B. C.Collins, and R.Aebersold, “Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial,” Mol. Syst. Biol., vol. 14, no. 8, p. e8126, Aug.2018.
  78. Y. S.Ting et al., “Peptide-Centric Proteome Analysis: An Alternative Strategy for the Analysis of Tandem Mass Spectrometry Data.,” Mol. Cell. Proteomics, vol. 14, no. 9, pp. 2301–2307, Sep.2015.
  79. S.Tyanova, T.Temu, and J.Cox, “The MaxQuant computational platform for mass spectrometry-based shotgun proteomics,” Nat. Protoc., vol. 11, p. 2301, Oct.2016.
  80. O.Bernhardt et al., Spectronaut: a fast and efficient algorithm for MRM-like processing of data independent acquisition (SWATH-MS) data. 2014.
  81. R. C.Poulos et al., “Strategies to enable large-scale proteomics for reproducible research,” Nat. Commun., vol. 11, no. 1, pp. 1–13, 2020.
  82. Institute for Systems Biology, “Spectrum Library Central at PeptideAtlas,” 2015. [Online]. Available: . [Accessed: 08-Oct-2019].
  83. H. L.Röst et al., “OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data.,” Nature biotechnology, vol. 32, no. 3. United States, pp. 219–223, Mar-2014.
  84. J.Wang et al., “MSPLIT-DIA: sensitive peptide identification for data-independent acquisition.,” Nature methods, vol. 12, no. 12. pp. 1106–1108, Dec-2015.
  85. Y.Yang, X.Liu, C.Shen, Y.Lin, P.Yang, and L.Qiao, “In silico spectral libraries by deep learning facilitate data-independent acquisition proteomics,” Nat. Commun., vol. 11, no. 1, p. 146, Jan.2020.
  86. S.Gessulat et al., “Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning,” Nat. Methods, vol. 16, no. 6, pp. 509–518, 2019.
  87. N. H.Tran et al., “Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry.,” Nat. Methods, vol. 16, no. 1, pp. 63–66, Jan.2019.
  88. A. M.Frank, M. M.Savitski, M. L.Nielsen, R. A.Zubarev, and P. A.Pevzner, “De novo peptide sequencing and identification with precision mass spectrometry.,” J. Proteome Res., vol. 6, no. 1, pp. 114–123, Jan.2007.
  89. R. S.Johnson and J. A.Taylor, “Searching sequence databases via De novo peptide sequencing by tandem mass spectrometry,” Mol. Biotechnol., vol. 22, no. 3, pp. 301–315, 2002.
  90. B.Ma et al., “PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry.,” Rapid Commun. Mass Spectrom., vol. 17, no. 20, pp. 2337–2342, 2003.
  91. Y.Li et al., “Group-DIA: analyzing multiple data-independent acquisition mass spectrometry data files.,” Nature methods, vol. 12, no. 12. United States, pp. 1105–1106, Dec-2015.
  92. Y. S.Ting et al., “PECAN: library-free peptide detection for data-independent acquisition tandem mass spectrometry data.,” Nat. Methods, vol. 14, no. 9, pp. 903–908, Sep.2017.
  93. C.-C.Tsou et al., “DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics.,” Nat. Methods, vol. 12, no. 3, pp. 258–64, 7 p following 264, Mar.2015.
  94. B. C.Searle et al., “Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry,” Nat. Commun., vol. 9, no. 1, p. 5128, 2018.
  95. P.Pandit, R.Patil, V.Palwe, S.Gandhe, R.Patil, and R.Nagarkar, “Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients,” Eur. J. breast Heal., vol. 16, no. 1, pp. 39–43, Nov.2019.
  96. C. K. Y.Ng, A. M.Schultheis, F.-C.Bidard, B.Weigelt, and J. S.Reis-Filho, “Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.,” J. Natl. Cancer Inst., vol. 107, no. 5, Feb.2015.
  97. Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours.,” Nature, vol. 490, no. 7418, pp. 61–70, Oct.2012.
  98. K.Rezaul et al., “Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics,” Genes and Cancer, vol. 1, no. 3, pp. 251–271, 2010.
  99. B. L. K.S. Cha, M.B. Imielinski, T. Rejtar, E.A. Richardson, D. Thakur, D.C. Sgroi, “In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology Mol Cell Proteomics, 9 (2010), pp. 2529-2544,” 2010.
  100. N. Q.Liu et al., “Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer,” J. Natl. Cancer Inst., vol. 106, no. 2, 2014.
  101. A. U.T. De Marchi, N.Q. Liu, C. Stingl, M.A. Timmermans, M. Smid, M.P. Look, M. Tjoa, R.B. Braakman, M. Opdam, S.C. Linn, F.C. Sweep, P.N. Span, M. Kliffen, T.M. Luider, J.A. Foekens, J.W. Martens, “4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer Mol Oncol, 10 (2016), pp. 24-39,” 2016.
  102. S.Tyanova, R.Albrechtsen, P.Kronqvist, J.Cox, M.Mann, and T.Geiger, “Proteomic maps of breast cancer subtypes,” Nat. Commun., vol. 7, no. 1, p. 10259, 2016.
  103. P. Mertins, D.R. Mani, K.V. Ruggles, M.A. Gillette, K.R. Clauser, P. Wang, “Proteogenomics connects somatic mutations to signalling in breast cancer Nature, 534 (2016), pp. 55-62,” 2016.
  104. H. J.Johansson et al., “Breast cancer quantitative proteome and proteogenomic landscape,” Nat. Commun., vol. 10, no. 1, p. 1600, 2019.
  105. P.Bouchal et al., “Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry,” Cell Rep., vol. 28, no. 3, pp. 832-843.e7, Jul.2019.
  106. T.Nagao, T.Kinoshita, T.Hojo, H.Tsuda, K.Tamura, and Y.Fujiwara, “The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.,” Breast, vol. 21, no. 3, pp. 289–295, Jun.2012.
  107. M. V.Dieci, E.Orvieto, M.Dominici, P.Conte, and V.Guarneri, “Rare Breast Cancer Subtypes : Histological , Molecular , and Clinical Peculiarities,” pp. 805–813, 2014.
  108. H.Zou et al., “P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas,” Oncol. Rep., vol. 39, no. 2, pp. 501–510, Feb.2018.
  109. M.Song et al., “Proteomic Analysis of Breast Cancer Tissues to Identify Biomarker Candidates by Gel-Assisted Digestion and Label-Free Quantification Methods Using LC-MS / MS,” vol. 35, no. 10, pp. 1839–1847, 2012.
  110. L. T.Li, G.Jiang, Q.Chen, and J. N.Zheng, “Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review),” Mol. Med. Rep., vol. 11, no. 3, pp. 1566–1572, 2015.
  111. F.Mantovani, L.Collavin, and G.DelSal, “Mutant p53 as a guardian of the cancer cell,” Cell Death Differ., vol. 26, no. 2, pp. 199–212, 2019.
  112. A. D.Sorrell, C. R.Espenschied, J. O.Culver, and J. N.Weitzel, “Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions,” Mol. Diagn. Ther., vol. 17, no. 1, pp. 31–47, Feb.2013.
  113. A. S.Al-Wajeeh et al., “Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer,” PLoS One, vol. 15, no. 1, pp. e0227404–e0227404, Jan.2020.
  114. J.-E.Lee et al., “Identification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion,” J. Proteomics, vol. 131, pp. 17–28, 2016.
  115. I.-H.Chen et al., “Phosphoproteins in extracellular vesicles as candidate markers for breast cancer,” Proc. Vol 1 (1&2) 28 Natl. Acad. Sci., vol. 114, no. 12, pp. 3175 LP – 3180, Mar.2017.
  116. H.Zhang et al., “SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1,” Br. J. Cancer, vol. 109, no. 10, pp. 2675–2684, Nov.2013.
  117. D.Liu and K.Zhou, “BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction,” Clin. Breast Cancer, vol. 20, no. 1, pp. 41-50.e8, 2020.
  118. H.-L.Jiang et al., “Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-beta/SMAD signaling.,” Oncotarget, vol. 6, no. 18, pp. 16352–16365, Jun.2015.
  119. B.Tang et al., “TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression,” J. Clin. Invest., vol. 112, no. 7, pp. 1116–1124, Oct.2003.
  120. X. C. L.Qian, H.Jiang, and J.Chen, “Ginsenoside Rg3 inhibits CXCR 4 expression and related migrations in a breast cancer cell line,” pp. 519–523, 2011.
  121. M.Zou, J.Wang, J.Gao, H.Han, and Y.Fang, “Phosphoproteomic analysis of the antitumor effects of ginsenoside Rg3 in human breast cancer cells,” Oncol. Lett., vol. 15, no. 3, pp. 2889–2898, Mar.2018.
  122. M. D. P.Lobo, F. B. M. B.Moreno, G. H. M. F.Souza, S. M. M. L.Verde, R. de A.Moreira, and A. C. de O.Monteiro-Moreira, “Label-free proteome analysis of plasma from patients with breast cancer: Stage-specific protein expression,” Front. Oncol., vol. 7, no. FEB, pp. 1–12, 2017.
  123. J.Beretov, V. C.Wasinger, E. K. A.Millar, P.Schwartz, P. H.Graham, and Y.Li, “Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach,” PLoS One, vol. 10, no. 11, 2015.
  124. “Human Proteome Atlas,” 2020. [Online]. Available: .
  125. WHO, Who Report on Cancer. 2020.
  126. NCI, “NCI Center to Reduce Cancer Health Disparities,” 2019. [Online]. Available: . [Accessed: 28-May-2019].
  127. A.Cooper, On the anatomy of the breast. Jefferson, 1840.
  128. M. L.Marinovich et al., “Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis,” BMC Cancer, vol. 15, p. 662, Oct.2015.
  129. M.Mayo Clinic, “Breast Cancer,” 2019, 2019. [Online]. Available: .
  130. C. J.Watson and W. T.Khaled, “Mammary development in the embryo and adult: a journey of morphogenesis and commitment,” Development, vol. 135, no. 6, pp. 995 LP – 1003, Mar.2008.
  131. J. H.Krege et al., “Generation and reproductive phenotypes of mice lacking estrogen receptor beta,” Proc. Natl.Acad.Sci. U.S.A., vol. 95, no. 26, pp. 15677–15682, Dec.1998.
  132. W.Ruan and D. L.Kleinberg, “Insulin-Like Growth Factor I Is Essential for Terminal End Bud Formation and Ductal Morphogenesis during Mammary Development1,” Endocrinology, vol. 140, no. 11, pp. 5075–5081, Nov.1999.
  133. J.McBryan, J.Howlin, S.Napoletano, and F.Martin, “Amphiregulin: Role in Mammary Gland Development and Breast Cancer,” J. Mammary Gland Biol. Neoplasia, vol. 13, pp. 159–169, Jul.2008.
  134. S. R.Oakes, H. N.Hilton, and C. J.Ormandy, “The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium,” Breast Cancer Res., vol. 8, no. 2, p. 207, 2006.
  135. T. R.Milanese et al., “Age-related lobular involution and risk of breast cancer.,” J. Natl. Cancer Inst., vol. 98, no. 22, pp. 1600–1607, Nov.2006.
  136. V.Sangwan and M.Park, “Receptor tyrosine kinases: role in cancer progression,” Curr. Oncol., vol. 13, no. 5, pp. 191–193, Oct.2006.
  137. S. P.Chiang, G. S.Karagiannis, J. S.Condeelis, and J. E.Segall, “Abstract 1844: Investigating the role of amphiregulin in breast cancer,” Cancer Res., vol. 77, no. 13 Supplement, pp. 1844 LP – 1844, Jul.2017.
  138. S.Lee et al., “Alterations of gene expression in the development of early hyperplastic precursors of breast cancer.,” Am. J. Pathol., vol. 171, no. 1, pp. 252–262, Jul.2007.
  139. S.Mao et al., “Abstract 5114: The role of amphiregulin in mammary gland development and breast cancer,” Cancer Res., vol. 78, no. 13 Supplement, pp. 5114 LP – 5114, Jul.2018.
  140. A.Baillo, C.Giroux, and S. P.Ethier, “Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer.,” J. Cell. Physiol., vol. 226, no. 10, pp. 2691–2701, Oct.2011.
  141. S.Rao, S. J. F.Cronin, V.Sigl, and J. M.Penninger, “RANKL and RANK: From Mammalian Physiology to Cancer Treatment,” Trends Cell Biol., vol. 28, no. 3, pp. 213–223, 2018.
  142. E.Gonzalez-Suarez et al., “RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.,” Nature, vol. 468, no. 7320, pp. 103–107, Nov.2010.
  143. D.Schramek et al., “Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.,” Nature, vol. 468, no. 7320, pp. 98–102, Nov.2010.
  144. D. C.Radisky and L. C.Hartmann, “Mammary involution and breast cancer risk: transgenic models and clinical studies,” J. Mammary Gland Biol. Neoplasia, vol. 14, no. 2, pp. 181–191, Jun.2009.
  145. R. W. E.Clarkson and C. J.Watson, “Microarray analysis of the involution switch.,” J. Mammary Gland Biol. Neoplasia, vol. 8, no. 3, pp. 309–319, Jul.2003.
  146. L.T.Bemis and P.Schedin, “Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion.,” Cancer Res., vol. 60, no. 13, pp. 3414–3418, Jul.2000.
  147. M.Xue et al., “Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56,” Oncogenesis, vol. 8, no. 5, p. 30, 2019.
  148. J.Wang and B.Xu, “Targeted therapeutic options and future perspectives for HER2-positive breast cancer,” Signal Transduct. Target. Ther., vol. 4, no. 1, p. 34, 2019.
  149. L.Xia et al., “Role of the NFκB-signaling pathway in cancer,” Onco. Targets. Ther., vol. 11, pp. 2063–2073, Apr.2018.
  150. T. H. B.Gomig et al., “Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer,” J. Proteomics, vol. 199, no. August 2018, pp. 1–14, 2019.
  151. E.Presti, Daniele and Quaquarini, “The PI3K/AKT/ mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments,” Cancers (Basel)., vol. 11, no. 9, pp. 1–20, 2019.
  152. B. M.Krishna et al., “Notch signaling in breast cancer: From pathway analysis to therapy,” Cancer Lett., vol. 461, pp. 123–131, 2019.
  153. M. A.Gillette et al., “Proteogenomics connects somatic mutations to signalling in breast cancer,” Nature, pp. 1–19, 2016.
  154. H. J.Burstein, “The distinctive nature of HER2- positive breast cancers.,” N. Engl. J. Med., vol. 353, no. 16, pp. 1652–1654, Oct.2005.
  155. NIH, “Breast Cancer,” 2019. [Online]. Available: .
  156. K. A.Metcalfe et al., “The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.,” Clin. Genet., vol. 93, no. 5, pp. 1063–1068, May2018.
  157. Z.Mitri, T.Constantine, and R.O’Regan, “The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy,” Chemother. Res. Pract., vol. 2012, p. 743193, 2012.
  158. M. C.Figueroa-Magalhães, D.Jelovac, R.Connolly, and A. C.Wolff, “Treatment of HER2-positive breast cancer,” Breast, vol. 23, no. 2, pp. 128–136, Apr.2014.
  159. M.Dowsett et al., “Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group,” J. Natl. Cancer Inst., vol. 103, no. 22, pp. 1656–1664, Nov.2011.
  160. M.Abubakar et al., “Combined quantitative measures of ER , PR , HER2 , and KI67 provide more prognostic information than categorical combinations in luminal breast cancer,” Mod. Pathol., pp. 1244–1256, 2019.
  161. F. J.Candido et al., “An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation,” pp. 1–13, 2017.
  162. A.Vaishnavi, A. T.Le, and R. C.Doebele, “TRKing down an old oncogene in a new era of targeted therapy.,” Cancer Discov., vol. 5, no. 1, pp. 25–34, Jan.2015.
  163. J. J.Lee, K.Loh, and Y.-S.Yap, “PI3K/Akt/mTOR inhibitors in breast cancer,” Cancer Biol. Med., vol. 12, no. 4, pp. 342–354, Dec.2015.
  164. O.Willis et al., “PIK3CA gene aberrancy and role in targeted therapy of solid malignancies,” Cancer Gene Ther., 2020.
  165. Y. F.Hou, M.F., Chen, Y.L., Tseng, T.F., Lin, C.M., Chen, M.S., Huang, C.J., Huang, Y.S., Hsieh, J.S., Huang, T.J., Jong, S.B., Huang, “Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer,” Kaohsiung J. Med. Sci., 1999.
  166. C.VanPoznak, L. N.Harris, and M. R.Somerfield, “Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline,” J. Oncol. Pract., vol. 11, no. 6, pp. 514–516, Jul.2015.
  167. A. M.Kabel, “Tumor markers of breast cancer: New prospectives,” J. Oncol. Sci., vol. 3, no. 1, pp. 5–11, 2017.
  168. X.Zhe, M. L.Cher, and R. D.Bonfil, “Circulating tumor cells: finding the needle in the haystack,” Am. J. Cancer Res., vol. 1, no. 6, pp. 740–751, 2011.
  169. W. A.Osta et al., “EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy,” Cancer Res., vol. 64, no. 16, pp. 5818 LP – 5824, Aug.2004.
  170. S.Cotterill, “Cancer Genetics Web,” 2019. [Online]. Available: . [Accessed: 10-Jul-2020].
  171. E.Jarasch, R. A. Y. B.Nagle, M.Kaufmann, C.Maurer, and W. J.Bocker, “Differential Diagnosis of Benign Epithelial Proliferations and Carcinomas of the Breast Using Antibodies to Cytokeratins,” 1987.
  172. Y.Jing, J.Zhang, S.Waxman, and R.Mira-y-Lopez, “Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent.,” Differentiation., vol. 60, no. 2, pp. 109–117, May1996.
  173. M. B.Lustberg et al., “Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.,” Breast Cancer Res., vol. 16, no. 2, p. R23, Mar.2014.
  174. C. P .Leo, C.Leo, and T. D.Szucs, “Breast cancer drug approvals by the US FDA from 1949 to 2018,” Nat. Rev. Drug Discov., vol. 19, no. 1, p. 11, 2020.
  175. A.Garcia-Diaz et al., “Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.,” Cell Rep., vol. 19, no. 6, pp. 1189–1201, May2017.
  176. Y.Han, D.Liu, and L.Li, “PD-1/PD-L1 pathway: current researches in cancer,” Am. J. Cancer Res., vol. 10, no. 3, pp. 727–742, Mar.2020.
  177. F.Schütz, S.Stefanovic, L.Mayer, A.VonAu, C.Domschke, and C.Sohn, “PD-1/PD-L1 Pathway in Breast Cancer,” Oncol. Res. Treat., vol. 40, no. 5, pp. 294–297, 2017.
  178. A.Illiano, G.Pinto, C.Melchiorre, A.Carpentieri, V.Faraco, and A.Amoresano, “Protein Glycosylation Investigated by Mass Spectrometry: An Overview,” Cells, vol. 9, no. 9, pp. 1–22, 2020.
  179. K. A.Resing and N. G.Ahn, “Proteomics strategies for protein identification,” vol. 579, pp. 885–889, 2005.
  180. G.Büyükköro臒lu, D. D.Dora, F.Özdemir, and C.H谋zel, “Chapter 15 - Techniques for Protein Analysis,” D.Barh and V. B. T.-O. T. and B.-E.Azevedo, Eds.Academic Press, 2018, pp. 317–351.
  181. T. J.Griffin and R.Aebersold, “Advances in Proteome Analysis by Mass Spectrometry,” J. Biol. Chem., vol. 276, no. 49, pp. 45497–45500, 2001.
  182. S. B.Nukala, G.Baron, G.Aldini, M.Carini, and A.D’Amato, “Mass Spectrometry-based Label-free Quantitative Proteomics To Study the Effect of 3PO Drug at Cellular Level.,” ACS Med. Chem. Lett., vol. 10, no. 4, pp. 577–583, Apr.2019.
  183. M. W.Duncan and S. W.Hunsucker, “Proteomics as a tool for clinically relevant biomarker discovery and validation.,” Exp. Biol. Med. (Maywood)., vol. 230, no. 11, pp. 808–817, Dec.2005.
  184. F. M.White, “Quantitative phosphoproteomic analysis of signaling network dynamics.,” Curr. Opin. Biotechnol., vol. 19, no. 4, pp. 404–409, Aug.2008.
  185. A. P.Frei et al., “Direct identification of ligand-receptor interactions on living cells and tissues.,” Nat. Biotechnol., vol. 30, no. 10, pp. 997–1001, Oct.2012.
  186. R.Aebersold and M.Mann, “Mass spectrometry-based proteomics,” Nature, vol. 422, no. 6928, pp. 198–207, 2003.
  187. F.Desiere et al., “The PeptideAtlas project.,” Nucleic Acids Res., vol. 34, no. Database issue, pp. 655–658, 2006.
  188. G.Rosenberger et al., “A repository of assays to quantify 10,000 human proteins by SWATH-MS,” Sci. Data, vol. 1, no. 1, p. 140031, 2014.
  189. P.Palmowski et al., “The Generation of a Comprehensive Spectral Library for the Analysis of the Guinea Pig Proteome by SWATH-MS,” Proteomics, vol. 19, no. 15, pp. 1–5, 2019.
  190. Y.Lin, “In silico spectral libraries by deep learning facilitate data-independent acquisition proteomics,” Nat. Commun., pp. 1–11, 2020.
  191. E.Hoedt, G.Zhang, and T. A.Neubert, “Stable isotope labeling by amino acids in cell culture (SILAC) for quantitative proteomics.,” Adv. Exp. Med. Biol., vol. 806, pp. 93–106, 2014.
  192. S.Wiese, K. A.Reidegeld, H. E.Meyer, and B.Warscheid, “Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research.,” Proteomics, vol. 7, no. 3, pp. 340–350, Feb.2007.
  193. J.Muntel et al., “Comparison of Protein Quantification in a Complex Background by DIA and TMT Workflows with Fixed Instrument Time,” 2019.
  194. L. R.Zieske, “A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies.,” J. Exp. Bot., vol. 57, no. 7, pp. 1501–1508, 2006.
  195. L.Zhang and J. E.Elias, “Relative Protein Quantification Using Tandem Mass Tag Mass Spectrometry BT - Proteomics: Methods and Protocols,” L.Comai, J. E.Katz, and P.Mallick, Eds.New York, NY: Springer New York, 2017, pp. 185–198.
  196. D.Virág et al., “Current Trends in the Analysis of Post-translational Modifications,” Chromatographia, vol. 83, no. 1, pp. 1–10, 2020.
  197. B.Manadas, V. M.Mendes, J.English, and M. J.Dunn, “Peptide fractionation in proteomics approaches.,” Expert Rev. Proteomics, vol. 7, no. 5, pp. 655–663, Oct.2010.
  198. E. R.Sauter, “Reliable Biomarkers to Identify New and Recurrent Cancer,” Eur. J. breast Heal., vol. 13, no. 4, pp. 162–167, Oct.2017.
  199. E. M.Woo, D.Fenyo, B. H.Kwok, H.Funabiki, and B. T.Chait, “Efficient Identification of Phosphorylation by Mass Spectrometric Phosphopeptide Fingerprinting,” Anal. Chem., vol. 80, no. 7, pp. 2419–2425, Apr.2008.
  200. S. A.Beausoleil et al., “Large-scale characterization of HeLa cell nuclear phosphoproteins,” Proc. Natl. Acad. Sci. U. S. A., vol. 101, no. 33, pp. 12130–12135, 2004.
  201. C.Ludwig, L.Gillet, G.Rosenberger, S.Amon, B. C.Collins, and R.Aebersold, “Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial,” Mol. Syst. Biol., vol. 14, no. 8, p. e8126, Aug.2018.
  202. Y. S.Ting et al., “Peptide-Centric Proteome Analysis: An Alternative Strategy for the Analysis of Tandem Mass Spectrometry Data.,” Mol. Cell. Proteomics, vol. 14, no. 9, pp. 2301–2307, Sep.2015.
  203. S.Tyanova, T.Temu, and J.Cox, “The MaxQuant computational platform for mass spectrometry-based shotgun proteomics,” Nat. Protoc., vol. 11, p. 2301, Oct.2016.
  204. O.Bernhardt et al., Spectronaut: a fast and efficient algorithm for MRM-like processing of data independent acquisition (SWATH-MS) data. 2014.
  205. R. C.Poulos et al., “Strategies to enable large-scale proteomics for reproducible research,” Nat. Commun., vol. 11, no. 1, pp. 1–13, 2020.
  206. Institute for Systems Biology, “Spectrum Library Central at PeptideAtlas,” 2015. [Online]. Available: . [Accessed: 08-Oct-2019].
  207. H. L.Röst et al., “OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data.,” Nature biotechnology, vol. 32, no. 3. United States, pp. 219–223, Mar-2014.
  208. J.Wang et al., “MSPLIT-DIA: sensitive peptide identification for data-independent acquisition.,” Nature methods, vol. 12, no. 12. pp. 1106–1108, Dec-2015.
  209. Y.Yang, X.Liu, C.Shen, Y.Lin, P.Yang, and L.Qiao, “In silico spectral libraries by deep learning facilitate data-independent acquisition proteomics,” Nat. Commun., vol. 11, no. 1, p. 146, Jan.2020.
  210. S.Gessulat et al., “Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning,” Nat. Methods, vol. 16, no. 6, pp. 509–518, 2019.
  211. N. H.Tran et al., “Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry.,” Nat. Methods, vol. 16, no. 1, pp. 63–66, Jan.2019.
  212. A. M.Frank, M. M.Savitski, M. L.Nielsen, R. A.Zubarev, and P. A.Pevzner, “De novo peptide sequencing and identification with precision mass spectrometry.,” J. Proteome Res., vol. 6, no. 1, pp. 114–123, Jan.2007.
  213. R. S.Johnson and J. A.Taylor, “Searching sequence databases via De novo peptide sequencing by tandem mass spectrometry,” Mol. Biotechnol., vol. 22, no. 3, pp. 301–315, 2002.
  214. B.Ma et al., “PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry.,” Rapid Commun. Mass Spectrom., vol. 17, no. 20, pp. 2337–2342, 2003.
  215. Y.Li et al., “Group-DIA: analyzing multiple data-independent acquisition mass spectrometry data files.,” Nature methods, vol. 12, no. 12. United States, pp. 1105–1106, Dec-2015.
  216. Y. S.Ting et al., “PECAN: library-free peptide detection for data-independent acquisition tandem mass spectrometry data.,” Nat. Methods, vol. 14, no. 9, pp. 903–908, Sep.2017.
  217. C.-C.Tsou et al., “DIA-Umpire: comprehensive computational framework for data-independent acquisition proteomics.,” Nat. Methods, vol. 12, no. 3, pp. 258–64, 7 p following 264, Mar.2015.
  218. B. C.Searle et al., “Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry,” Nat. Commun., vol. 9, no. 1, p. 5128, 2018.
  219. P.Pandit, R.Patil, V.Palwe, S.Gandhe, R.Patil, and R.Nagarkar, “Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients,” Eur. J. breast Heal., vol. 16, no. 1, pp. 39–43, Nov.2019.
  220. C. K. Y.Ng, A. M.Schultheis, F.-C.Bidard, B.Weigelt, and J. S.Reis-Filho, “Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.,” J. Natl. Cancer Inst., vol. 107, no. 5, Feb.2015.
  221. Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours.,” Nature, vol. 490, no. 7418, pp. 61–70, Oct.2012.
  222. K.Rezaul et al., “Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics,” Genes and Cancer, vol. 1, no. 3, pp. 251–271, 2010.
  223. B. L. K.S. Cha, M.B. Imielinski, T. Rejtar, E.A. Richardson, D. Thakur, D.C. Sgroi, “In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology Mol Cell Proteomics, 9 (2010), pp. 2529-2544,” 2010.
  224. N. Q.Liu et al., “Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer,” J. Natl. Cancer Inst., vol. 106, no. 2, 2014.
  225. A. U.T. De Marchi, N.Q. Liu, C. Stingl, M.A. Timmermans, M. Smid, M.P. Look, M. Tjoa, R.B. Braakman, M. Opdam, S.C. Linn, F.C. Sweep, P.N. Span, M. Kliffen, T.M. Luider, J.A. Foekens, J.W. Martens, “4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer Mol Oncol, 10 (2016), pp. 24-39,” 2016.
  226. S.Tyanova, R.Albrechtsen, P.Kronqvist, J.Cox, M.Mann, and T.Geiger, “Proteomic maps of breast cancer subtypes,” Nat. Commun., vol. 7, no. 1, p. 10259, 2016.
  227. P. Mertins, D.R. Mani, K.V. Ruggles, M.A. Gillette, K.R. Clauser, P. Wang, “Proteogenomics connects somatic mutations to signalling in breast cancer Nature, 534 (2016), pp. 55-62,” 2016.
  228. H. J.Johansson et al., “Breast cancer quantitative proteome and proteogenomic landscape,” Nat. Commun., vol. 10, no. 1, p. 1600, 2019.
  229. P.Bouchal et al., “Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry,” Cell Rep., vol. 28, no. 3, pp. 832-843.e7, Jul.2019.
  230. T.Nagao, T.Kinoshita, T.Hojo, H.Tsuda, K.Tamura, and Y.Fujiwara, “The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.,” Breast, vol. 21, no. 3, pp. 289–295, Jun.2012.
  231. M. V.Dieci, E.Orvieto, M.Dominici, P.Conte, and V.Guarneri, “Rare Breast Cancer Subtypes : Histological , Molecular , and Clinical Peculiarities,” pp. 805–813, 2014.
  232. H.Zou et al., “P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas,” Oncol. Rep., vol. 39, no. 2, pp. 501–510, Feb.2018.
  233. M.Song et al., “Proteomic Analysis of Breast Cancer Tissues to Identify Biomarker Candidates by Gel-Assisted Digestion and Label-Free Quantification Methods Using LC-MS / MS,” vol. 35, no. 10, pp. 1839–1847, 2012.
  234. L. T.Li, G.Jiang, Q.Chen, and J. N.Zheng, “Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review),” Mol. Med. Rep., vol. 11, no. 3, pp. 1566–1572, 2015.
  235. F.Mantovani, L.Collavin, and G.DelSal, “Mutant p53 as a guardian of the cancer cell,” Cell Death Differ., vol. 26, no. 2, pp. 199–212, 2019.
  236. A. D.Sorrell, C. R.Espenschied, J. O.Culver, and J. N.Weitzel, “Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions,” Mol. Diagn. Ther., vol. 17, no. 1, pp. 31–47, Feb.2013.
  237. A. S.Al-Wajeeh et al., “Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer,” PLoS One, vol. 15, no. 1, pp. e0227404–e0227404, Jan.2020.
  238. J.-E.Lee et al., “Identification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion,” J. Proteomics, vol. 131, pp. 17–28, 2016.
  239. I.-H.Chen et al., “Phosphoproteins in extracellular vesicles as candidate markers for breast cancer,” Proc. Vol 1 (1&2) 28 Natl. Acad. Sci., vol. 114, no. 12, pp. 3175 LP – 3180, Mar.2017.
  240. H.Zhang et al., “SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1,” Br. J. Cancer, vol. 109, no. 10, pp. 2675–2684, Nov.2013.
  241. D.Liu and K.Zhou, “BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction,” Clin. Breast Cancer, vol. 20, no. 1, pp. 41-50.e8, 2020.
  242. H.-L.Jiang et al., “Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-beta/SMAD signaling.,” Oncotarget, vol. 6, no. 18, pp. 16352–16365, Jun.2015.
  243. B.Tang et al., “TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression,” J. Clin. Invest., vol. 112, no. 7, pp. 1116–1124, Oct.2003.
  244. X. C. L.Qian, H.Jiang, and J.Chen, “Ginsenoside Rg3 inhibits CXCR 4 expression and related migrations in a breast cancer cell line,” pp. 519–523, 2011.
  245. M.Zou, J.Wang, J.Gao, H.Han, and Y.Fang, “Phosphoproteomic analysis of the antitumor effects of ginsenoside Rg3 in human breast cancer cells,” Oncol. Lett., vol. 15, no. 3, pp. 2889–2898, Mar.2018.
  246. M. D. P.Lobo, F. B. M. B.Moreno, G. H. M. F.Souza, S. M. M. L.Verde, R. de A.Moreira, and A. C. de O.Monteiro-Moreira, “Label-free proteome analysis of plasma from patients with breast cancer: Stage-specific protein expression,” Front. Oncol., vol. 7, no. FEB, pp. 1–12, 2017.
  247. J.Beretov, V. C.Wasinger, E. K. A.Millar, P.Schwartz, P. H.Graham, and Y.Li, “Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach,” PLoS One, vol. 10, no. 11, 2015.
  248. “Human Proteome Atlas,” 2020. [Online]. Available: .

Tools


Copyright © 2026  糖心原创 Exclusively distributed by